Docetaxel Injection, Solution, Concentrate
Product Images NDC 0955-1021

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0955-1021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Docetaxel 01)

Chemical structure of docetaxel, showing its complex molecular arrangement with multiple rings, hydroxyl groups, methyl groups, and associated hydrogen atoms, including a trihydrate component (3 H2O).*

FDA Label Image

Figure 1 (Docetaxel 02)

A line graph depicting disease-free survival (DFS) probability (%) over time in months for two treatment groups labeled TAC and FAC. The x-axis represents disease-free survival time in months, ranging from 0 to 66, and the y-axis shows DFS probability as a percentage from 0 to 100. The TAC group is represented by a solid line, and the FAC group by a dotted line, with both showing a general decline in DFS probability over time.*

FDA Label Image

Figure 2 (Docetaxel 03)

A survival probability graph comparing two treatment groups labeled TAC and FAC, plotting survival probability percentage over survival time in months up to approximately 66 months. The graph shows survival probability declining over time for both groups with TAC generally higher than FAC.*

FDA Label Image

Figure 3 (Docetaxel 04)

A survival curve graph showing cumulative probability over survival time in months. Two groups are compared: T75 (solid line) and BSC (dashed line). The graph illustrates overall survival differences with a log-rank p value of 0.010, indicating statistical comparison of the two curves.*

FDA Label Image

Figure 4 (Docetaxel 05)

A Kaplan-Meier survival curve chart showing cumulative probability of overall survival over time in months. Two groups, labeled T75 and V/I, are plotted with solid and dashed lines respectively. The chart includes a log-rank p-value of 0.13 comparing overall survival between the groups.*

FDA Label Image

Figure 5 (Docetaxel 06)

A survival curve chart depicting survival probability over time in months, comparing two groups labeled T75 q3w and M q3w. The y-axis shows survival probability from 0 to 1.0, and the x-axis shows survival time up to 30 months.*

FDA Label Image

Figure 6 (Docetaxel 07)

A line graph showing probability (%) over time (months) up to 24 months for two groups labeled TCF and CF. The probability decreases over time for both groups, with the TCF group maintained at higher probability levels compared to the CF group throughout the time period.*

FDA Label Image

Figure 7 (Docetaxel 08)

A Kaplan-Meier survival curve displaying survival probability (%) over survival time in months. Two groups, TCF and CF, are compared with TCF represented by a solid line and CF by a dotted line, showing probability decline from near 100% at month 0 to below 20% by month 36.*

FDA Label Image

Figure 8 (Docetaxel 09)

A Kaplan-Meier curve depicting progression-free survival (PFS) probability over time in months. The graph compares two groups labeled TPF (solid line) and PF (dotted line), showing the decline in PFS probability for both across a 42-month period.*

FDA Label Image

Figure 9 (Docetaxel 10)

A line graph showing survival probability (%) on the vertical axis against survival time (months) on the horizontal axis. Two survival curves are displayed, labeled as TPF and PF, illustrating differences in survival over time up to 72 months.*

FDA Label Image

Figure 10 (Docetaxel 11)

A Kaplan-Meier survival curve displaying survival probability (%) over survival time in months for two patient groups: TPF (n=255) and PF (n=246). The graph shows declining survival rates over 72 months, with the TPF group consistently exhibiting higher survival probability than the PF group. The number of patients at risk is listed below the x-axis at various time intervals.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Packaging label for Docetaxel Injection 80 mg/4 mL (20 mg/mL) solution concentrate for intravenous use. The label shows it is a single 4 mL single-dose vial with instructions to discard unused portion. It is manufactured by Sanofi-Aventis U.S. LLC under the Winthrop brand. The NDC code is 0955-1021-04.*

FDA Label Image

Principal Display Panel (1 mL Vial Carton)

The packaging label for Docetaxel Injection 20 mg/mL by Winthrop, a Sanofi company, is shown. It is an intravenous injection, solution concentrate provided in a 1 mL single-dose vial. The label highlights that the product is ready to add to infusion solution and emphasizes discarding any unused portion. The label includes the NDC 0955-1020-01 and manufacturer information for Sanofi-Aventis U.S. LLC.*

FDA Label Image

Principal Display Panel (8 mL Vial Carton)

Packaging label for Docetaxel Injection 160 mg/8 mL (20 mg/mL) concentrate for intravenous use, produced by Winthrop, a Sanofi company. The label indicates it contains one 8 mL single-dose vial and mentions it is ready to add to infusion solution. The label includes the NDC number 0955-1022-08 and cautions to discard unused portions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.